Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 2,374 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

In-Home Care for Patients With PSP and Related Disorders

NCT03552484
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Dementia With Lewy Bodies, Multiple System Atrophy, Corticobasal Syndrome, Atypical Parkinson Disease
Interventions
Home Visit Program, Usual Care/Online Survey
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 22, 2026, 9:19 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)

NCT06852768
View directory record Official record
Conditions
oGHVD
Interventions
d-MAPPS, Placebo, PI and Patient Masked
Biological · Other
Lead sponsor
Regenerative Ocular Immunobiologics LLC
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Beverly Hills, California • Huntington Beach, California • Palm Harbor, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)

NCT01539239
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
Hydrus Aqueous Implant, Cataract surgery
Device · Procedure
Lead sponsor
Ivantis, Inc.
Industry
Eligibility
45 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
26
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 22, 2026, 9:19 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Female Acl Prevention Study Where we Look at Landing Techniques Pre/Post Nine Week Strenghtening Program

NCT01729312
View directory record Official record
Conditions
Prevention of ACL Thru Strengthening Program
Interventions
Not listed
Lead sponsor
Henry Ford Health System
Other
Eligibility
13 Years to 16 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Farmington, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Technology-based Eye Care Services (TECS) Compare

NCT02558712
View directory record Official record
Conditions
Cataract, Macular Degeneration, Glaucoma
Interventions
Technology-based Eye Care Services (TECS) Protocol
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 22, 2026, 9:19 PM EDT
Recruiting Not applicable Interventional

Home-based Vision Rehabilitation Guided by Brain Imaging

NCT07635329
View directory record Official record
Conditions
Visual Field Defect, Stroke, Hemianopia Homonymous, Quadrantanopia, Cortical Blindness, Visual Field Defect, Peripheral, Visual Field Loss, Traumatic Brain Injury, Brain Tumor
Interventions
High-level perceptual learning-based training, Low-level perceptual learning-based training
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

The Support, Educate, Empower (SEE) Program

NCT04735653
View directory record Official record
Conditions
Glaucoma
Interventions
Personalized Glaucoma Coaching, Enhanced Standard care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Clinical Evaluation of Approved Contact Lenses

NCT02540122
View directory record Official record
Conditions
Vision Disorders
Interventions
Marketed Contact Lens 1, Marketed Contact Lens 2, Marketed Contact Lens 3, Marketed Contact Lens 4
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Oct 22, 2026, 9:19 PM EDT
Completed No phase listed Observational

Brain Connectivity Between Visual Input and Movement

NCT00376545
View directory record Official record
Conditions
Occipital Cortex, Prefrontal Cortex, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 9:19 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ultrasonic Evaluation of Ocular Tissues

NCT00279695
View directory record Official record
Conditions
Glaucoma, Tumors, Age-Related Macular Degeneration
Interventions
high frequency ultrasound examination
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 22, 2026, 9:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Will Listening to Music Make it Easier to Take a Visual Field Test?

NCT01027039
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2016 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT04742283
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
41
States / cities
Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of PDP-716

NCT03450629
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
2 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
47
States / cities
Chandler, Arizona • Prescott, Arizona • Sun City, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 22, 2026, 9:19 PM EDT
Completed No phase listed Observational

Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema

NCT02088229
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 1 Interventional

NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement

NCT01408472
View directory record Official record
Conditions
Glaucoma, Primary Open Angle
Interventions
NT-501 CNTF Implant
Drug
Lead sponsor
Jeffrey L Goldberg
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT00538304
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost eye drops, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?

NCT02622178
View directory record Official record
Conditions
Glaucoma Diagnosis
Interventions
Optical Coherence Tomography, Visual evoked potential
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Gene Therapy for Achromatopsia (CNGA3)

NCT03758404
View directory record Official record
Conditions
Achromatopsia
Interventions
adeno-associated virus vector AAV- CNGA3
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

RMP-A03 Ocular Suspension in Patients With Pterygium

NCT05794204
View directory record Official record
Conditions
Pterygium
Interventions
RMP-A03 - Dose 1, RMP-A03 - Dose 2, RMP-A03 Placebo
Drug
Lead sponsor
Suzhou Raymon Pharmaceuticals Company, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Glendale, California • Inglewood, California • Newport Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 22, 2026, 9:19 PM EDT
Completed No phase listed Observational

4 Repeat Tauopathy Neuroimaging Initiative

NCT01804452
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions
Observational Study
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 90 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 22, 2026, 9:19 PM EDT
Suspended Not applicable Interventional

Comparative Efficacy of Saccadic and Biofeedback Training in Homonymous Hemianopia

NCT06638619
View directory record Official record
Conditions
Hemianopia, Homonymous
Interventions
Biofeedback Fixation Training, Saccadic Reading Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 9:19 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 22, 2026, 9:19 PM EDT
Completed Not applicable Interventional

Eyelid Closure in Glaucoma Therapy

NCT00832832
View directory record Official record
Conditions
Glaucoma
Interventions
Eyelid closure, No intervention will be assigned
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 22, 2026, 9:19 PM EDT
Terminated Phase 2 Interventional

A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

NCT00788541
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 6 mg/mL, Anecortave Acetate Sterile Suspension, 3.75 mg/mL, Anecortave Acetate Sterile Suspension, 96 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2012 · Synced Oct 22, 2026, 9:19 PM EDT